Therapeutic targeting of SPINK1-positive prostate cancer

Science Translational Medicine

Volumn 3, Issue 72, 2011, Pages

  Ateeq, Bushra ^a,b   Tomlins, Scott A ^a,b   Laxman, Bharathi ^a,b   Asangani, Irfan A ^a,b   Cao, Qi ^a,b   Cao, Xuhong ^a,b   Li, Yong ^a,b   Wang, Xiaoju ^a,b   Feng, Felix Y ^a,b,c   Pienta, Kenneth J ^a,b   Varambally, Sooryanarayana ^a,b   Chinnaiyan, Arul M ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN; RECOMBINANT PROTEIN; SERINE PEPTIDASE INHIBITOR KAZAL TYPE 1; SERINE PROTEINASE INHIBITOR; SPINK1 ANTIBODY; SPINK1 PROTEIN; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG; CARRIER PROTEIN; HYBRID PROTEIN; SPINK1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TARGETING; GENE FUSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; AUTOCRINE EFFECT; BAGG ALBINO MOUSE; CANCER INVASION; CANCER TRANSPLANTATION; CELL LINE; GENE TARGETING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOCRINE COMMUNICATION; CARRIER PROTEINS; CELL LINE; CELL PROLIFERATION; GENE TARGETING; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79952345420     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001498     Document Type: Article

References (36)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. B. E. Helgeson, S. A. Tomlins, N. Shah, B. Laxman, Q. Cao, J. R. Prensner, X. Cao, N. Singla, J. E. Montie, S. Varambally, R. Mehra, A. M. Chinnaiyan, Characterization of TMPRSS2: ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73-80 (2008).
3. S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, R. B. Shah, K. J. Pienta, M. A. Rubin, A. M. Chinnaiyan, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
4. S. A. Tomlins, R.Mehra, D. R. Rhodes, L. R. Smith, D. Roulston, B. E. Helgeson, X. Cao, J. T. Wei, M. A. Rubin, R. B. Shah, A. M. Chinnaiyan, TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396-3400 (2006).
5. S. A. Tomlins, B. Laxman, S. M. Dhanasekaran, B. E. Helgeson, X. Cao, D. S. Morris, A. Menon, X. Jing, Q. Cao, B. Han, J. Yu, L. Wang, J. E. Montie, M. A. Rubin, K. J. Pienta, D. Roulston, R. B. Shah, S. Varambally, R. Mehra, A. M. Chinnaiyan, Distinct classes of chromosomal re-arrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599 (2007).
6. S. A. Tomlins, A. Bjartell, A. M. Chinnaiyan, G. Jenster, R. K. Nam, M. A. Rubin, J. A. Schalken, ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur. Urol. 56, 275-286 (2009).
7. Y. Zong, L. Xin, A. S. Goldstein, D. A. Lawson, M. A. Teitell, O. N. Witte, ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl. Acad. Sci. U.S.A. 106, 12465-12470 (2009).
8. J. C. King, J. Xu, J. Wongvipat, H. Hieronymus, B. S. Carver, D. H. Leung, B. S. Taylor, C. Sander, R. D. Cardiff, S. S. Couto,W. L. Gerald, C. L. Sawyers, Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526 (2009).
9. B. S. Carver, J. Tran, A. Gopalan, Z. Chen, S. Shaikh, A. Carracedo, A. Alimonti, C. Nardella, S. Varmeh, P. T. Scardino, C. Cordon-Cardo, W. Gerald, P. P. Pandolfi, Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
10. S. A. Tomlins, D. R. Rhodes, J. Yu, S. Varambally, R. Mehra, S. Perner, F. Demichelis, B. E. Helgeson, B. Laxman, D. S. Morris, Q. Cao, X. Cao, O. Andrén, K. Fall, L. Johnson, J. T. Wei, R. B. Shah, H. Al-Ahmadie, J. A. Eastham, S. E. Eggener, S. W. Fine, K. Hotakainen, U. H. Stenman, A. Tsodikov, W. L. Gerald, H. Lilja, V. E. Reuter, P. W. Kantoff, P. T. Scardino, M. A. Rubin, A. S. Bjartell, A. M. Chinnaiyan, The role of SPINK1 in ETS rearrangementnegative prostate cancers. Cancer Cell 13, 519-528 (2008).
11. L. A. Kazal, D. S. Spicer, R. A. Brahinsky, Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J. Am. Chem. Soc. 70, 3034-3040 (1948).
12. E. Kelloniemi, E. Rintala, P. Finne, U. H. Stenman; Finnbladder Group, Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62, 249-253 (2003).
13. A. Lukkonen, S. Lintula, K. von Boguslawski, O. Carpén, B. Ljungberg, G. Landberg, U. H. Stenman, Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int. J. Cancer 83, 486-490 (1999).
14. C. Haglund, M. L. Huhtala, H. Halila, S. Nordling, P. J. Roberts, T. M. Scheinin, U. H. Stenman, Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br. J. Cancer 54, 297-303 (1986).
15. M. Higashiyama, T. Monden, N. Tomita, M. Murotani, Y. Kawasaki, H. Morimoto, A. Murata, T. Shimano, M. Ogawa, T. Mori, Expression of pancreatic secretory trypsin inhibitor (PSTI) in colorectal cancer. Br. J. Cancer 62, 954-958 (1990).
16. M. L. Huhtala, K. Kahanpää, M. Seppälä, H. Halila, U. H. Stenman, Excretion of a tumorassociated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int. J. Cancer 31, 711-714 (1983).
17. A. Paju, J. Vartiainen, C. Haglund, O. Itkonen, K. von Boguslawski, A. Leminen, T. Wahlström, U. H. Stenman, Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: Prognostic study on tissue and serum. Clin. Cancer Res. 10, 4761-4768 (2004).
18. Y. Ohmachi, A. Murata, N. Matsuura, T. Yasuda, T. Yasuda, M. Monden, T. Mori, M. Ogawa, K. Matsubara, Specific expression of the pancreatic-secretory- trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int. J. Cancer 55, 728-734 (1993).
19. A. Bjartell, A. Paju, W. M. Zhang, V. Gadaleanu, J. Hansson, G. Landberg, U. H. Stenman, Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 64, 29-39 (2005).
20. B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins, A. M. Chinnaiyan, A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645-649 (2008).
21. K. A. Leinonen, T. T. Tolonen, H. Bracken, U. H. Stenman, T. L. Tammela, O. R. Saramäki, T. Visakorpi, Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin. Cancer Res. 16, 2845-2851 (2010).
22. K. Hotakainen, A. Bjartell, A. Sankila, R. Järvinen, A. Paju, E. Rintala, C. Haglund, U. H. Stenman, Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int. J. Oncol. 28, 95-101 (2006).
23. A. Dagvadorj, S. H. Tan, Z. Liao, L. R. Cavalli, B. R. Haddad, M. T. Nevalainen, Androgenregulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin. Cancer Res. 14, 6062-6072 (2008).
24. L. T. Hunt, W. C. Barker, M. O. Dayhoff, Epidermal growth factor: Internal duplication and probable relationship to pancreatic secretory trypsin inhibitor. Biochem. Biophys. Res. Commun. 60, 1020-1028 (1974).
25. D. C. Bartelt, R. Shapanka, L. J. Greene, The primary structure of the human pancreatic secretory trypsin inhibitor. Amino acid sequence of the reduced S-aminoethylated protein. Arch. Biochem. Biophys. 179, 189-199 (1977).
26. A. Zijlstra, R. Mellor, G. Panzarella, R. T. Aimes, J. D. Hooper, N. D. Marchenko, J. P. Quigley, A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 62, 7083-7092 (2002).
27. V. Gouyer, D. Fontaine, P. Dumont, O. de Wever, H. Fontayne-Devaud, E. Leteurtre, S. Truant, D. Delacour, H. Drobecq, J. P. Kerckaert, Y. de Launoit, M. Bracke, C. Gespach, J. L. Desseyn, G. Huet, Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 27, 4024-4033 (2008).
28. X. Lu, J. Lamontagne, F. Lu, T. M. Block, Tumor-associated protein SPIK/TATI suppresses serine protease dependent cell apoptosis. Apoptosis 13, 483-494 (2008).
29. L. A. Scheving, Primary amino acid sequence similarity between human epidermal growth factor-urogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch. Biochem. Biophys. 226, 411-413 (1983).
30. J. Mendelsohn, J. Baselga, The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
31. N. Ozaki, M. Ohmuraya, M. Hirota, S. Ida, J. Wang, H. Takamori, S. Higashiyama, H. Baba, K. Yamamura, Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol. Cancer Res. 7, 1572-1581 (2009).
32. S. F. Slovin, W. K. Kelly, A. Wilton, M. Kattan, P. Myskowski, J. Mendelsohn, H. I. Scher, Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin. Genitourin. Cancer 7, E77-E82 (2009).
33. C. Nabhan, T. M. Lestingi, A. Galvez, K. Tolzien, S. K. Kelby, D. Tsarwhas, S. Newman, J. D. Bitran, Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: Final results of a phase II trial. Urology 74, 665-671 (2009).
34. C. Pezaro, M. A. Rosenthal, H. Gurney, I. D. Davis, C. Underhill, M. J. Boyer, D. Kotasek, B. Solomon, G. C. Toner, An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am. J. Clin. Oncol. 32, 338-341 (2009).
35. E. H. van der Horst, J. H. Leupold, R. Schubbert, A. Ullrich, H. Allgayer, TaqMan-based quantification of invasive cells in the chick embryo metastasis assay. Biotechniques 37, 940-942, 944, 946 (2004).
36. Acknowledgments: We thank X. Jiang, X. Jing, A. Yocum, J. Siddiqui, K. Suleman, R. Mehra, and C. A. Maher for the technical assistance; M. Dhanasekaran and C. Brenner for discussions; and J. Granger for critically reading the manuscript. Funding: This work is supported in part by the Department of Defense W81XWH-08-1-0031, Early Detection Research Network UO1 CA111275, Prostate SPORE P50CA69568, and NIH (R01CA132874). A.M.C. is supported by the Doris Duke Charitable Foundation Clinical Scientist Award, Burroughs Welcome Foundation Award in Clinical Translational Research, and the Prostate Cancer Foundation (PCF). A.M.C. is an American Cancer Society research professor. B.A. is supported by the Genentech Foundation Postdoctoral Fellowship and Young Investigator Award from the Expedition Inspiration Fund for Breast Cancer Research. S.A.T. is supported by a Young Investigator Award from the PCF. Q.C. is supported by U.S. Department of Defense (PC094725). S.V. is supported by a Prostate Cancer SPORE Career Development award. Author contributions: B.A., S.A.T., and A.M.C. designed the research plan and wrote the manuscript; B.A., B.L., Q.C., and X.C. performed the in vitro experiments; I.A.A. performed CAM assays; B.A. performed in vivo xenograft experiments; B.A., B.L., I.A.A., S.A.T., F.Y.F., K.J.P., S.V., and A.M.C. analyzed the data. Competing interests: The University of Michigan has filed for patents on SPINK1, on which A.M.C., B.A., and S.A.T. are named as inventors. A.M.C. is a consultant for Gen-Probe Inc. S.A.T. has consulted for Cougar Biotechnology, AstraZeneca, and Compendia Biosciences. The diagnostic field of use has been licensed to Gen-Probe Inc. Gen-Probe was not involved in the design or funding of these studies. The other authors declare that they have no competing interests.